First AD

Second AD

Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

Please discuss long term follow up data from the phase 2 KEYNOTE-B61 study investigatingpembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC. 

Please provide a brief background surrounding KEYNOTE-B61 

How did the response rates compare across histologies?

Considering the observed OS benefit with adjuvant pembro, do you intend to approach its adjuvant use in a similar or different manner in this treatment setting?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC  

Laurence Albiges, MD, PhD, analyzes the long-term follow-up data from the phase 2 KEYNOTE-B61 study, highlighting the observed overall survival (OS) rate associated with adjuvant pembrolizumab. 

Dr Albiges Reviews Long term follow up data from KEYNOTE-B61 